Curious to see the emissions of the organizations you buy from or invest in?
Book a demo for a pilot project
Book a demo for a pilot project
Akeso, Inc., a prominent player in the pharmaceutical preparation manufacturing industry, is headquartered in China (CN) and operates extensively across various regions. Founded in 2012, Akeso has rapidly established itself as a leader in the development and production of innovative biopharmaceuticals, particularly monoclonal antibodies and small molecule drugs.
The company is renowned for its unique approach to drug development, focusing on precision medicine and targeted therapies that address unmet medical needs. With a robust pipeline of products, Akeso has achieved significant milestones, including successful clinical trials and partnerships that enhance its market position. As a result, Akeso continues to make strides in the global pharmaceutical landscape, contributing to advancements in healthcare and patient outcomes.
-15 vs industry average
Akeso’s score of 27 is lower than 39% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Pharmaceutical Preparation Manufacturing is among the most carbon-intensive industries
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
Scope 3 accounts for ••• of total emissions.
Akeso, a Pharmaceutical Preparation Manufacturing company headquartered in CN, reported its 2024 Scope 1 emissions at approximately 6,408,460 kg CO2e and its location-based Scope 2 emissions at about 46,019,810 kg CO2e. In 2023, the company's Scope 1 emissions were approximately 1,397,580 kg CO2e, and Scope 2 emissions totalled around 26,831,850 kg CO2e. For 2022, Akeso's Scope 1 emissions were about 82,000 kg CO2e, with Scope 2 emissions at approximately 23,658,020 kg CO2e. The earliest reported data, from 2021, shows Scope 1 emissions of approximately 35,230 kg CO2e and Scope 2 emissions of about 4,495,650 kg CO2e. Akeso does not currently disclose Scope 3 emissions data. The company has not publicly committed to any specific emissions reduction targets, such as those verified by the Science Based Targets initiative (SBTi), nor has it joined The Climate Pledge. Emissions performance data is sourced directly from Akeso, Inc.
No climate goals have been disclosed for Akeso yet.
No scope 3 category breakdown has been disclosed yet.


PCAF scored Scope 1, 2 and 3 for 2M+ organizations, including private ones.
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more